Pharmacogenomics of Antiretroviral Drug Metabolism and Transport

被引:7
|
作者
Yu, Zaikuan J. [1 ]
Mosher, Eric P. [1 ]
Bumpus, Namandje N. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
来源
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 | 2021年 / 61卷
基金
美国国家卫生研究院;
关键词
pharmacogenomics; drug metabolism; HIV medication; drug-drug interactions; personalized medicine; REVERSE-TRANSCRIPTASE INHIBITOR; HIV-1 PROTEASE INHIBITORS; CONSORTIUM CPIC GUIDELINE; BLOOD MONONUCLEAR-CELLS; GENETIC-VARIANTS; PHARMACOKINETIC INTERACTIONS; CLINICAL PHARMACOKINETICS; INTEGRASE INHIBITORS; P-GLYCOPROTEIN; EFAVIRENZ;
D O I
10.1146/annurev-pharmtox-021320-111248
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antiretroviral therapy has markedly reduced morbidity and mortality for persons living with human immunodeficiency virus (HIV). Individual tailoring of antiretroviral regimens has the potential to further improve the long-term management of HIV through the mitigation of treatment failure and drug-induced toxicities. While the mechanisms underlying anti-HIV drug adverse outcomes are multifactorial, the application of drug-specific pharmacogenomic knowledge is required in order to move toward the personalization of HIV therapy. Thus, detailed understanding of the metabolism and transport of antiretrovirals and the influence of genetics on these pathways is important. To this end, this review provides an up-to-date overview of the metabolism of anti-HIV therapeutics and the impact of genetic variation in drug metabolism and transport on the treatment of HIV. Future perspectives on and current challenges in pursuing personalized HIV treatment are also discussed.
引用
收藏
页码:565 / 585
页数:21
相关论文
共 50 条
  • [1] Pharmacogenomics of immunosuppressive drug metabolism
    Fredericks, S
    Holt, DW
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (06) : 607 - 613
  • [2] Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions
    Holstein, Andreas
    Beil, Winfried
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (03) : 225 - 241
  • [3] Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism
    Banerjee, Basu Dev
    Kumar, Ranjeet
    Thamineni, Krishna Latha
    Shah, Harendra
    Thakur, Gaurav Kumar
    Sharma, Tusha
    CURRENT DRUG METABOLISM, 2019, 20 (14) : 1103 - 1113
  • [4] Pregnancy and pharmacogenomics in the context of drug metabolism and response
    Hellden, Anders
    Madadi, Parvaz
    PHARMACOGENOMICS, 2013, 14 (14) : 1779 - 1791
  • [5] Teratogenicity of antiepileptic drugs: role of drug metabolism and pharmacogenomics
    Sankar, R.
    ACTA NEUROLOGICA SCANDINAVICA, 2007, 116 (01): : 65 - 71
  • [6] Pharmacogenomics of antiretroviral therapy
    Haas, DW
    DRUG DEVELOPMENT RESEARCH, 2004, 62 (03) : 213 - 220
  • [7] The clinical implications of antiretroviral pharmacogenomics
    Fox, Julie
    Boffito, Marta
    Winston, Alan
    PHARMACOGENOMICS, 2006, 7 (04) : 587 - 596
  • [8] Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited
    Fuhr, Uwe
    Hsin, Chih-hsuan
    Li, Xia
    Jabrane, Wafaa
    Soergel, Fritz
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59, 2019, 59 : 507 - 536
  • [9] Pharmacogenomics: the future of drug therapy
    Tsai, YJ
    Hoyme, HE
    CLINICAL GENETICS, 2002, 62 (04) : 257 - 264
  • [10] Pharmacogenomics: the genomics of drug response
    March, R
    YEAST, 2000, 17 (01) : 16 - 21